Health Canada has granted approval for GlaxoSmithKline’s ( GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The FTSE 100 index slumped 99.42 points, 1.2%, at 8,025.77. The FTSE 250 closed down 295.73 points, 1.4%, at 20,427.80. The AIM All-Share fell 7.07 points, 1.0%, at 730.86.

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

Initiated the Phase 2 MoonStone trial, a Phase 2, multicenter, randomized, double-blind, placebo-controlled trial, to evaluate the efficacy and safety of obexelimab in patients with Relapsing Multiple ...

GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...